Clomifene

Estrogen Agonist/Antagonist — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Clomifene is an ofp drug in the Estrogen Agonist/Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1967. Its mechanism of action is classified as Selective Estrogen Receptor Modulators. DrugCentral lists 33 molecular targets, including EBP, ESR1 and SIGMAR1. Recorded indications include Controlled ovarian stimulation, Female infertility, Induction of spermatogenesis and Ovulation induction.

• Approval status: ofp (first approved 1967 by the FDA).
• Drug class: Estrogen Agonist/Antagonist.
• Mechanism of action: Selective Estrogen Receptor Modulators.
• Molecular targets: EBP, ESR1, SIGMAR1 and Pgrmc1 (33 listed in DrugCentral).
• Indications: Controlled ovarian stimulation, Female infertility, Induction of spermatogenesis and Ovulation induction.
• ATC code: G03GB02 (Ovulation stimulants, synthetic).
• Molecular formula: C26H28ClNO; molecular weight 405.97 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Controlled ovarian stimulation
• Female infertility
• Induction of spermatogenesis
• Ovulation induction

Off-label uses (5)

• Corpus Luteum Insufficiency Syndrome
• Diagonstic Test for Hypothalamic Pituitary Gonadal Axis
• Male infertility
• Oligozoospermia
• Ovarian Function Studies

Contraindications (19)

• Cyst of ovary
• Depressive disorder
• Disease of liver
• Endometrial carcinoma
• Endometriosis
• Hypothyroidism
• Intermenstrual bleeding - irregular
• Lesion of brain
• Neoplasm of pituitary gland
• Ovarian hyperstimulation syndrome
• Polycystic ovaries
• Pregnancy, function
• Scotomata
• Severe adrenal insufficiency
• Thromboembolic disorder
• Thrombophlebitis
• Thyrotoxicosis
• Visual Disturbance of Seeing Spots
• Visual impairment

Mechanism & targets

• Mechanism of action (MoA): Selective Estrogen Receptor Modulators
• Established pharmacologic class: Estrogen Agonist/Antagonist

Molecular targets (33)

Target	Gene	Action	Activity
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	EBP	unknown	Ki 9.00
Estrogen receptor	ESR1	modulator	Ki 8.89
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 8.10
Membrane-associated progesterone receptor component 1	Pgrmc1	unknown	Ki 7.52
C-8 sterol isomerase	ERG2	unknown	Ki 6.80
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 6.75
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.67
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 6.64
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 6.47
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 6.46
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.46
Muscarinic acetylcholine receptor M1	CHRM1	unknown	Ki 6.41
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 6.36
D(3) dopamine receptor	DRD3	unknown	Ki 6.35
Sodium-dependent dopamine transporter	SLC6A3	unknown	Ki 6.21
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 6.18
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.14
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 6.07
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 6.06
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 6.03

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2022-03-11	PMDA	—	Fuji Pharma Co., Ltd
1967-02-01	FDA	—	SANOFI AVENTIS US

ATC classification

ATC code	Therapeutic hierarchy
G03GB02	GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › GONADOTROPINS AND OTHER OVULATION STIMULANTS › Ovulation stimulants, synthetic

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Exposure during pregnancy	251.8
Ovarian hyperstimulation syndrome	198.2
Heterotopic pregnancy	183.7
Abortion spontaneous	161.6
Foetal exposure during pregnancy	124.6
Adnexal torsion	121.8
Abortion	118.3
Multiple pregnancy	111.9
Gestational diabetes	102.7
Ectopic pregnancy	96.5
Maternal exposure before pregnancy	91.7
Premature baby	81.9

Chemical structure

• Molecular formula: C₂₆H₂₈ClNO
• Molecular weight: 405.97 g/mol
• CAS number: —
• InChIKey: GKIRPKYJQBWNGO-UHFFFAOYSA-N
• PubChem CID: 1548955

CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Clomifene used for?

DrugCentral lists the following indications for Clomifene: Controlled ovarian stimulation, Female infertility, Induction of spermatogenesis and Ovulation induction.

How does Clomifene work?

Clomifene is classified as Selective Estrogen Receptor Modulators; its molecular targets in DrugCentral include EBP, ESR1 (modulator), SIGMAR1 and Pgrmc1.

When was Clomifene first approved?

Clomifene was first approved by the FDA in 1967.

What drug class does Clomifene belong to?

Clomifene is in the Estrogen Agonist/Antagonist class.

What is the chemical formula of Clomifene?

Clomifene has the molecular formula C26H28ClNO and a molecular weight of 405.97 g/mol.

Sources

• DrugCentral drug card 700 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2355051 — compound record and bioactivity
• PubChem CID 1548955 — chemical identifiers
• DrugBank DB00882 — drug record
• FDA UNII 1HRS458QU2 — substance identity
• DailyMed: FDA labels for Clomifene — current prescribing information (label search)
• UniProt Q15125 (EBP) — target protein
• UniProt P03372 (ESR1) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt Q12809 (KCNH2) — target protein
• UniProt P18825 (ADRA2C) — target protein
• UniProt P08173 (CHRM4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.